The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Protective Alterations in Phase 1 and 2 Metabolism of Aflatoxin B1 by Oltipraz in Residents of Qidong, People's Republic of China
Abstract
BACKGROUND: Residents of Qidong, People's Republic of China, are at high risk for development of hepatocellular carcinoma, in part due to consumption of foods contaminated with aflatoxins, which require metabolic activation to become carcinogenic. In a randomized, placebo-controlled, double-blind phase IIa chemoprevention trial, we tested oltipraz, an antischistosomal drug that has been shown to be a potent and effective inhibitor of aflatoxin-induced hepatocarcinogenesis in animal models. METHODS: In 1995, 234 adults from Qidong were enrolled. Healthy eligible individuals were randomly assigned to receive by mouth 125 mg oltipraz daily, 500 mg oltipraz weekly, or a placebo. Sequential immunoaffinity chromatography and liquid chromatography coupled to mass spectrometry or to fluorescence detection were used to identify and quantify phase 1 and phase 2 metabolites of aflatoxin B1 in the urine of study participants. Reported P values are two-sided. RESULTS: One month of weekly administration of 500 mg oltipraz led to a 51% decrease in median levels of the phase 1 metabolite aflatoxin M1 excreted in urine compared with administration of a placebo (P = .030), but it had no effect on levels of a phase 2 metabolite, aflatoxin-mercapturic acid (P = .871). By contrast, daily intervention with 125 mg oltipraz led to a 2.6-fold increase in median aflatoxin-mercapturic acid excretion (P = .017) but had no effect on excreted aflatoxin M1 levels (P = .682). CONCLUSIONS: Intermittent, high-dose oltipraz inhibited phase 1 activation of aflatoxins, and sustained low-dose oltipraz increased phase 2 conjugation of aflatoxin, yielding higher levels of aflatoxin-mercapturic acid. While both mechanisms can contribute to protection, this study highlights the feasibility of inducing phase 2 enzymes as a chemopreventive strategy in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimation of Average Concentration in the Presence of Nondetectable Values
Hornung, R. W., & Reed, L. D. (1990) · Applied Occupational and Environmental Hygiene · doi:10.1080/1047322x.1990.10389587 · Cited by 3,495
Chang, M.-H., Chen, C.-J., Lai, M.-S., Hsu, H.-M., Wu, T.-C., Kong, M.-S., Liang, D.-C., Shau, W.-Y., & Chen, D.-S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706263362602 · Cited by 1,883
Zhang, Y., Talalay, P., Cho, C. G., & Posner, G. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2399 · Cited by 1,682
Fahey, J. W., Zhang, Y., & Talalay, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10367 · Cited by 1,376
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
(2008) · Encyclopedia of Genetics, Genomics, Proteomics and Informatics · doi:10.1007/978-1-4020-6754-9_2795 · Cited by 1,243
Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma
Ross, R. K., Yu, M. C., Henderson, B. E., Yuan, J.-M., Qian, G.-S., Tu, J.-T., Gao, Y.-T., Wogan, G. N., & Groopman, J. D. (1992) · The Lancet · doi:10.1016/0140-6736(92)91528-g · Cited by 725
Self-citationQian, G.-S., Ross, R. K., Yu, M. C., Yuan, J., Gao, Y. T., Henderson, B. E., Wogan, G. N., & Groopman, J. D. (1994) · PubMed · Cited by 666
Self-citationThe toxicology of aflatoxins: human health, veterinary and agricultural significance.
Eaton, D. L., & Groopman, J. D. (1993) · Cited by 597
Self-citationPrimary prevention of hepatocellular carcinoma
YU, S. (1995) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1995.tb01370.x · Cited by 434
Benson, A. M., Batzinger, R. P., Ou, S.-Y. L., Bueding, E., Cha, Y., & Talalay, P. (1978) · PubMed · Cited by 337
Gallagher, E. P., Kunze, K. L., Stapleton, P. L., & Eaton, D. L. (1996) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.0326 · Cited by 267
Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan
Wang, L.-Y., Hatch, M., Chen, C.-J., Levin, B., You, S.-L., Lu, S.-N., Wu, M.-H., Wu, W.-P., Wang, L.-W., Wang, Q., et al. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960904)67:5<620::aid-ijc5>3.0.co;2-w · Cited by 259
Kensler, T. W., Egner, P. A., Dolan, P. M., Groopman, J. D., & Roebuck, B. D. (1987) · PubMed · Cited by 240
Self-citationCarcinogenic effects of low dietary levels of aflatoxin B1 in rats
Wogan, G. N., Paglialunga, S., & Newberne, P. M. (1974) · Food and Cosmetics Toxicology · doi:10.1016/0015-6264(74)90239-9 · Cited by 215
Groopman, J. D., Zhu, J. Q., Donahue, P. R., Pikul, A., Zhang, L., Chen, J., & Wogan, G. N. (1992) · PubMed · Cited by 203
Self-citationRaney, K. D., Meyer, D. J., Ketterer, B., Harris, T. M., & Guengerich, F. P. (1992) · Chemical Research in Toxicology · doi:10.1021/tx00028a004 · Cited by 191
Gan, L.-S., Skipper, P. L., Peng, X., Groopman, J. D., Chen, J.-S., Wogan, G. N., & Tannenbaum, S. R. (1988) · Carcinogenesis · doi:10.1093/carcin/9.7.1323 · Cited by 189
Self-citationRoebuck, B. D., Liu, Y. L., Rogers, A. E., Groopman, J. D., & Kensler, T. W. (1991) · PubMed · Cited by 162
Self-citationCorrelation of dietary aflatoxin B1 levels with excretion of aflatoxin M1 in human urine.
Zhu, J., Zhang, L., Hu, X., Xiao, Y., Chen, J., Xu, Y., Frémy, J. M., & Chu, F. S. (1987) · PubMed · Cited by 155
Langouët, S., Coles, B. C., Morel, F., et al. (1995) · PubMed · Cited by 152
Ansher, S. S., Dolan, P., & Bueding, E. (1983) · Hepatology · doi:10.1002/hep.1840030608 · Cited by 144
Kensler, T. W., He, X., Otieno, M. A., Egner, P. A., Jacobson, L. P., Chen, B., Wang, J., Zhu, Y., Zhang, B.-C., Wang, J. B., et al. (1998) · PubMed · Cited by 129
Self-citationJacobson, L. P., Zhang, B. C., Zhu, Y. R., Wang, J. B., Wu, Y., Zhang, Q. N., Yu, L., Qian, G., Kuang, S. Y., Li, Y. F., et al. (1997) · PubMed · Cited by 116
Self-citationYu, M., Lien, J.-P., Chiu, Y. H., Santella, R. M., Liaw, Y., & Chen, C. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80178-x · Cited by 111
Morel, F., Fardel, O., Meyer, D. J., Langouët, S., Gilmore, K. S., Meunier, B., Tu, C. D., Kensler, T. W., KETTERER, B., & Guillouzo, A. (1993) · PubMed · Cited by 110
Self-citationShiraki, H., & Guengerich, F. P. (1984) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(84)90257-1 · Cited by 109
Groopman, J. D., DeMatos, P., Egner, P. A., Love-Hunt, A., & Kensler, T. W. (1992) · Carcinogenesis · doi:10.1093/carcin/13.1.101 · Cited by 92
Self-citationDavidson, N. E., Egner, P. A., & Kensler, T. W. (1990) · PubMed · Cited by 84
Self-citationO'Dwyer, P. J., Szarka, C. E., Yao, K.-S., Halbherr, T., Pfeiffer, G. R., Green, F., Gallo, J. M., Brennan, J., Frucht, H., Goosenberg, E. B., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118904 · Cited by 83
Oltipraz: A laboratory and clinical review
Benson, A. B. (1993) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240531041 · Cited by 74
Induction of hepatic heme oxygenase-1 and ferritin in rats by cancer chemopreventive dithiolethiones
Primiano, T., Kensler, T. W., Kuppusamy, P., Zweier, J. L., & Sutter, T. R. (1996) · Carcinogenesis · doi:10.1093/carcin/17.11.2291 · Cited by 69
Self-citationPharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent.
Gupta, E., Olopade, O. I., Ratain, M. J., et al. (1995) · PubMed · Cited by 64
Primiano, T. (1998) · Carcinogenesis · doi:10.1093/carcin/19.6.999 · Cited by 62
Kensler, T. W., Gange, S. J., Egner, P. A., Dolan, P. M., Muñoz, Á., Groopman, J. D., Rogers, A. E., & Roebuck, B. D. (1997) · PubMed · Cited by 53
Self-citationScholl, P. F., Musser, S. M., & Groopman, J. D. (1997) · Chemical Research in Toxicology · doi:10.1021/tx960161+ · Cited by 49
Self-citationOltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China.
Zhang, B. C., Zhu, Y. R., Wang, J. B., Wu, Y., Zhang, Q. N., Qian, G. S., Kuang, S. Y., Li, Y. F., Fang, X., Yu, L., et al. (1997) · PubMed · Cited by 33
Self-citationTownsend, A. J., Fields, W. R., Haynes, R. L., Doss, A. J., Li, Y., Doehmer, J., & Morrow, C. S. (1998) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00175-0 · Cited by 31
The chemopreventive agent oltipraz stimulates repair of damaged DNA.
O'Dwyer, P. J., Johnson, S. W., Khater, C., Krueger, A., Matsumoto, Y., Hamilton, T. C., & Yao, K.-S. (1997) · PubMed · Cited by 27
Scholl, P. F., Musser, S. M., Kensler, T. W., & Groopman, J. D. (1996) · Carcinogenesis · doi:10.1093/carcin/17.6.1385 · Cited by 20
Self-citation
Cited by
Cancer burden in the year 2000. The global picture
Parkin, D. M., Bray, F. I., & Devesa, S. S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00267-2 · Cited by 2,169
“In a small-scale trial in China [198], a relatively large dose of oltipraz has been shown to reduce the level of albumin–aflatoxin adducts in humans.”
BackgroundWilliams, J. H., Phillips, T. D., Jolly, P. E., Stiles, J. K., Jolly, C. M., & Aggarwal, D. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.5.1106 · Cited by 1,781
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
The emerging role of the Nrf2–Keap1 signaling pathway in cancer
Jaramillo, M. C., & Zhang, D. D. (2013) · Genes & Development · doi:10.1101/gad.225680.113 · Cited by 1,297
Ramos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
Self-citation
Metadata
- Authors
- Wang, J.-S., Shen, X., He, X., Zhu, Y.-R., Zhang, B.-C., Wang, J.-B., Qian, G.-S., Kuang, S.-Y., Zarba, A., Egner, P. A., Jacobson, L. P., Munoz, A., Helzlsouer, K. J., Groopman, J. D., & Kensler, T. W.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-02-17
- Volume
- 91
- Issue
- 4
- Pages
- 347-354
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2152404909
- Cited by
- 307
- References
- 40
- FWCI
- 28.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.